个人简介：
刘甘强博士，现任中山大学医学院教授、博士生导师，国家重大人才工程（青年项目）入选者。2007年本科毕业于同济大学生命科学与技术学院生物信息学专业。2014年于澳大利亚昆士兰大学获得生物信息学博士学位（师从著名分子生物学家John Mattick教授，澳大利亚科学院院士；澳大利亚技术科学与工程学院院士；澳大利亚健康与医学科学院院士），同年赴哈佛大学医学院/布莱根妇女医院Clemens Scherzer神经基因组课题组(帕金森病高级研究中心)进行博士后研究。2017年10月起担任哈佛大学医学院神经病学系讲师/布莱根妇女医院助理科学家。2018年11月获聘中山大学“百人计划”引进人才加入中山大学医学院，入选2019年广东省“珠江人才计划”青年拔尖人才，2021年深圳市海外高层次人才B类。
研究方向：
神经退行性疾病精准医学；医学大数据和人工智能
教育经历：
2010.08～2014.10 澳大利亚昆士兰大学，博士
2007.09～2010.07 同济大学生命科学与技术学院，硕士
2003.09～2007.07 同济大学生命科学与技术学院，本科
学科专业：
生物信息学，神经病学精准医学
研究概述：
刘甘强教授团队开展组学大数据整合的生物信息学和神经病学精准医学的交叉和转化研究，以数据驱动的方式为疾病的诊断和进展发掘潜在的生物标志物和提供相应的预测工具。近年来，课题组在帕金森病进展异质性研究方面取得了重要学术成果：
（1）揭示遗传变异与帕金森病进展之间的关联，发现b-葡萄糖脑苷脂酶基因突变、线粒体单倍型群和帕金森病患者的认知功能下降存在遗传关联，开发适用于临床应用的遗传认知风险评分预测帕金森病患者的全面认知障碍。
（2）开发了全基因组生存分析(GWSS)方法，发现与帕金森病痴呆相关的全新遗传位点，同时构建了多基因危险评分预测帕金森患者进展性痴呆，为延缓或阻止患者疾病进展中的认知障碍发掘了新的潜在药物靶点，拓展了疾病新的治疗方向。
（3）探索帕金森病多组学生物标志物，发现了与帕金森病发生发展相关的各种体液标记,利用机器学习方法构建疾病诊断和预测进展的相关工具。
科研项目：
国家自然科学面上项目（32270701）在研，主持
国家自然科学基金青年项目（31900475）在研，主持
广东省科技厅“珠江人才计划”青年拔尖人才项目（2019QN01Y139）在研，主持
广东省基础与应用基础研究基金自然科学基金面上项目（2022A1515011440）在研，主持
深圳市基础研究专项（自然科学基金）基础研究面上项目（JCYJ20190807161601692）在研，主持
中山大学高校基本科研业务费创新人才培育计划项目（22ykqb07）在研，主持
中山大学青年培育项目（19ykpy146）已结题，主持
学术兼职：
国际计算生物学学会会员，美国神经学会会员，国际帕金森与运动障碍协会会员。国家自然科学基金、广东省自然科学基金、深圳市基础研究基金评审专家。广东省党外知识分子联谊会第四届理事。
招生与招聘：
诚挚欢迎具有生物信息学、生物统计学、遗传学和临床神经病学背景专职科研人员，博士后加盟，我们将提供有竞争力的薪酬待遇与职业发展环境。长期招收博士生，硕士生，有意者请发详细个人简历到本人邮箱。研究生招生信息详见中山大学研究生招生网（https://graduate.sysu.edu.cn/zsw/）。
联系方式：
liugq3@mail.sysu.edu.cn
著作
1 Liu G*, Ni C, Zhan J, Li W, Luo J, Liao Z, Locascio JJ, Xian W, Chen L, Pei Z, Corvol JC , Maple-Grødem Jodi, Campbell MC, Elabz A, Lesage S, Brice A, Huang AY, Schwarzschild MA, Hayes MT, Wills A, Ravina B, Sholuson I, Taba P, Kõks S, Beach TG, Cormier-Dequaire F, Alves G, Tysnes OB, Perlmutter JS, Heutink P, van Hilten JJ, Barker RA, Williams-Gray CH. Scherzer CR* and IGPP. Mitochondrial haplogroups and cognitive progression in Parkinson’s disease. Brain. 2022 Nov 8. PMID: 36343661.
2 Luo J, Wu H, Li X, Xian W, Li W, Joseph J. J, Pei Z, Liu G*. Joint modeling study identifies blood-based transcripts link to cognitive decline in Parkinson’s. Movement Disorders. 2022 Sep 10. PMID: 36087011.
3 Liu G, Peng J, Liao Z, Locascio JJ, Corvol JC, Zhu Frank, Dong X, Maple-Grødem Jodi, Campbell MC, Elabz A, Lesage S, Brice A, Mangone G, Growdon JH, Huang AY, Schwarzschild MA, Hayes MT, Wills A, Herrington TM, Ravina B, Sholuson I, Taba P, Kõks S, Beach TG, Cormier-Dequaire F, Alves G, Tysnes OB, Perlmutter JS, Heutink P, Amr SS, van Hilten JJ, Kasten M, Mollenhauer B, Trenkwalder C, Klein C, Barker RA, Williams-Gray CH. Marinus J, IGPP, Scherzer CR. Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson's disease. Nature Genetics. 2021 Jun; 53 (6):787-793. PMID:33958783.
4 Liu G, Locascio JJ, Corvol JC, Boot B, Liao Z, Page K, Franco D, Burke K, Jansen IE, Trisini-Lipsanopoulos A, Winder-Rhodes S, Tanner CM, Lang AE, Eberly S, Elbaz A, Brice A, Mangone G, Ravina B, Shoulson I, Cormier-Dequaire F, Heutink P, van Hilten JJ, Barker RA, Williams-Gray CH, Marinus J, Scherzer CR, for the HBS, CamPaIGN, PICNICS, PROPARK, PSG, DIGPD and PDBP investigators. Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts. Lancet Neurology. 2017; 16(8): 620-629.
5 Liu G, Boot B, Locascio JJ, Jansen IE, Winder-Rhodes S, Eberly S, Elbaz A, Brice A, Ravina B, van Hilten JJ, Cormier-Dequaire F, Corvol JC, Barker RA, Heutink P, Marinus J, Williams-Gray CH, Scherzer CR; International Genetics of Parkinson Disease Progression (IGPP) Consortium. Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's. Annals of Neurology. 2016; 80(5): 674-685.
6 Szwedo AA, Dalen I, Pedersen KF, Camacho M, Bäckström D, Forsgren L, Tzoulis C, Winder-Rhodes S, Hudson G, Liu G, Scherzer CR, Lawson RA, Yarnall AJ, Williams-Gray CH, Macleod AD, Counsell CE, Tysnes O, Alves G, Maple-Grødem J*. GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study. Movement Disorders. 2022 Feb 2; 36(1):106-117. PMID: 35106798
7 Huh YE, Park H, Chiang MSR, Tuncali I, Liu G, Locascio JJ, Shirvan J, Hutten SJ, Rotunno MS, Viel C, Shihabuddin LS, Wang B, Sardi SP, Scherzer CR*. Glucosylceramide in cerebrospinal fluid of patients with GBA-associated and idiopathic Parkinson's disease enrolled in PPMI. NPJ parkinson’s disease. 2021 Nov 22;7(1):102. PMID: 34811369
8 Jonkhout N, Cruciani S, Santos Vieira HG, Tran J, Liu H, Liu G, Pickford R, Kaczorowski D, Franco GR, Vauti F, Camacho N, Abedini SS, Najmabadi H, Ribas de Pouplana L, Christ D, Schonrock N, Mattick JS, Novoa EM. Subcellular relocalization and nuclear redistribution of the RNA methyltransferases TRMT1 and TRMT1L upon neuronal activation. RNA Biology. 2021 Jan 27. PMID: 33499731.
9 Guo X, Deng B, Zhong L, Xie F, Qiu Q, Wei X, Wang W, Xu J, Liu G, Tsun Hon, WP, Yenari M, Zhu S, Wang Q. Fibrinogen is an Independent Risk Factor for White Matter Hyperintensities in CADASIL but not in Sporadic Cerebral Small Vessel Disease Patients. Aging and Disease.2021 June 1, 12(3):801-811. PMID:34094643
10 Iwaki H, Blauwendraat C, Leonard HL, Makarious MB, Kim JJ, Liu G, Maple-Grødem J, Corvol JC, Pihlstrøm L, van Nimwegen M, Smolensky L, Amondikar N, Hutten SJ, Frasier M, Nguyen KH, Rick J, Eberly S, Faghri F, Auinger P, Scott KM, Wijeyekoon R, Van Deerlin VM, Hernandez DG, Gibbs RJ, Day-Williams AG, Brice A, Alves G, Noyce AJ, Tysnes OB, Evans JR, Breen DP, Estrada K, Wegel CE, Danjou F, Simon DK, Andreassen OA, Ravina B, Toft M, Heutink P, Bloem BR, Weintraub D, Barker RA, Williams-Gray CH, van de Warrenburg BP, Van Hilten JJ, Scherzer CR, Singleton AB, Nalls MA. Differences in the Presentation and Progression of Parkinson's Disease by Sex. Movement Disorders. 2021 Jan; 36(1):106-117 PMID: 33002231
11 Huh YE, Ruby Chiang MS, Locascio JJ, Liao Z, Liu G, Choudhury K, Kuras YI, Tuncali I, Videnovic A, Hunt AL, Schwarzschild MA, Hung AY, Herrington TM, Hayes MT, Hyman BT, Wills AM, Gomperts SN, Growdon JH, Sardi SP, Scherzer CR. β-Glucocerebrosidase activity in GBA-linked Parkinson disease: The type of mutation matters. Neurology. 2020 August 11; 95(6): e685-e696; PMID:32540937
12 Stoker TB, Camacho M, Winder-Rhodes S, Liu G, Scherzer CR, Foltynie T, Evans J, Breen DP, Barker RA, Williams-Gray CH. Impact of GBA1 variants on long-term clinical progression and mortality in incident Parkinson's disease. Journal of Neurology Neurosurgery & Psychiatry. 2020 July; 91(7):695-702, PMID:32303560
13 Stoker TB, Camacho M, Winder-Rhodes S, Liu G, Scherzer CR, Foltynie T, Barker RA, Williams-Gray CH. A common polymorphism in SNCA is associated with accelerated motor decline in GBA-Parkinson's disease. Journal Neurology Neurosurgery & Psychiatry. 2020 Jun; 91(6):673-674.
14 Iwaki H, Blauwendraat C, Leonard HL, Kim JJ, Liu G, Maple-Grødem J, Corvol JC, Pihlstrøm L, van Nimwegen M, Hutten SJ, Nguyen KH, Rick J, Eberly S, Faghri F, Auinger P, Scott KM, Wijeyekoon R, Van Deerlin VM, Hernandez DG, Gibbs JR; International Parkinson's Disease Genomics Consortium, Chitrala KN, Day-Williams AG, Brice A, Alves G, Noyce AJ, Tysnes OB, Evans JR, Breen DP, Estrada K, Wegel CE, Danjou F, Simon DK, Andreassen O, Ravina B, Toft M, Heutink P, Bloem BR, Weintraub D, Barker RA, Williams-Gray CH, van de Warrenburg BP, Van Hilten JJ, Scherzer CR, Singleton AB, Nalls MA. Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. Movement Disorders. 2019; Dec;34(12):1839-1850.
15 Iwaki H, Blauwendraat C, Leonard HL, Liu G, Maple-Grødem J, Corvol JC, Pihlstrøm L, van Nimwegen M, Hutten SJ, Nguyen KH, Rick J, Eberly S, Faghri F, Auinger P, Scott KM, Wijeyekoon R, Van Deerlin VM, Hernandez DG, Day-Williams AG, Brice A, Alves G, Noyce AJ, Tysnes OB, Evans JR, Breen DP, Estrada K, Wegel CE, Danjou F, Simon DK, Ravina B, Toft M, Heutink P, Bloem BR, Weintraub D, Barker RA, Williams-Gray CH, van de Warrenburg BP, Van Hilten JJ, Scherzer CR, Singleton AB, Nalls MA. Genetic risk of Parkinson disease and progression: An analysis of 13 longitudinal cohorts. Neurology Genetics. 2019; Jul 9;5(4):e348
16 Henderson-Smith A, Fisch KM, Hua J, Liu G, Ricciardelli E, Jepsen K, Huentelman M, Stalberg G, Edland SD, Scherzer CR, Dunckley T Desplats P. DNA methylation changes associated with Parkinson's disease progression: outcomes from the first longitudinal genome-wide methylation analysis in blood. Epigenetics. 2019; Mar 14:1-18.
17 Dong X, Liao Z, Gritsch D, Hadzhiev Y, Bai Y, Locascio JJ, Guennewig B, Liu G, Blauwendraat C, Wang T, Adler CH, Hedreen JC, Faull RLM, Frosch MP, Nelson PT, Rizzu P, Cooper AA, Heutink P, Beach TG, Mattick JS, Müller F & Scherzer CR. Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric disease. Nature Neuroscience. 2018; 21(10):1482-1492
18 Locascio JJ, Eberly S, Liao Z, Liu G, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Dhima K, Hung AY, Flaherty AW, Schwarzschild MA, Hayes MT, Wills AM, Shivraj Sohur U, Mejia NI, Selkoe DJ, Oakes D, Shoulson I, Dong X, Marek K, Zheng B, Ivinson A, Hyman BT, Growdon JH, Sudarsky LR, Schlossmacher MG, Ravina B, Scherzer CR. Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease. Brain. 2015; 138(9): 2659-2671.
19 Liu G, Mercer TR, Shearwood AM, Siira SJ, Hibbs ME, Mattick JS, Rackham O, Filipovska A. Mapping of mitochondrial RNA-protein Interactions by digital RNase footprinting. Cell Reports. 2013; 5(3): 839-848.
20 Liu G, Mattick JS, Taft RJ. A meta-analysis of the genomic and transcriptomic composition of complex life. Cell Cycle. 2013; 12(13): 2061-2072.
